It is still unknown whether liquid biopsies are a reliable mechanism for determining disease prognosis outside of prostate cancer.
One potentially revolutionary hypothesis relates to the evolutionary processes involved in oncogenesis.
Patients with diabetes, hypercholesterolemia, or CAD had 23.9%, 11.4%, and 19.2% increased costs, respectively, versus those without risk factors for CVD.
The authors found that BRCA1-positive patients who became pregnant had improved disease-free survival, although there was no improvement in overall survival.
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results.
Secondary end points were not significantly different between the 2 groups, including overall survival.
It is still unclear why patients in the experimental arm in BELLINI saw a worse overall survival (OS) rate than those receiving placebo.
As understanding of cancer improves, drug development could become accelerated, necessitating a means for determining whether a drug is actually effective.
With the rising rates of cancer diagnosis and increasing cost of treatment, delays in time to treatment initiation can be seen as primarily policy related.
Some chemotherapeutic drugs have been shown to stimulate the immune system, despite the historical belief that chemotherapies are immunosuppressive.
